New York: Allergan plc Ordinary Shares (NYSE:AGN) Stock Has Just Had Its Buy Rating Reiterated by Deutsche Bank. Shares now Have a $273 Target

July 17, 2017 - By Marguerite Chambers

 New York: Allergan plc Ordinary Shares (NYSE:AGN) Stock Has Just Had Its Buy Rating Reiterated by Deutsche Bank. Shares now Have a $273 Target

Investors sentiment decreased to 0.5 in 2016 Q4. Its down 3.50, from 4 in 2016Q3. It turned negative, as 4 investors sold Allergan plc Ordinary Shares shares while 4 reduced holdings. 2 funds opened positions while 2 raised stakes. 69,049 shares or 57.17% less from 161,234 shares in 2016Q3 were reported.

Frontier Investment Mgmt invested 0.78% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Chartist Inc Ca reported 1,562 shares or 0% of all its holdings. Mitchell Mcleod Pugh Williams Inc reported 0.68% stake. Cubic Asset Mngmt Limited Liability Company holds 2,100 shares. Legacy Capital Prns Inc reported 1,940 shares. Connors Investor Service holds 1,000 shares. Gemmer Asset Limited Liability Company holds 0.01% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 120 shares. Eqis Cap Mgmt Inc owns 5,297 shares. Dowling & Yahnke Limited Company stated it has 1,530 shares. Amer Rech & Mngmt Company holds 33 shares. 463 were reported by Bartlett And Limited Liability Corporation. Grassi Investment reported 8,275 shares. Armstrong Henry H Assoc has 0.16% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 3,690 shares.

Allergan plc Ordinary Shares (NYSE:AGN) Rating Reaffirmed

New York: In analysts report shared with investors on Monday morning, Deutsche Bank reiterated their Buy rating on Allergan plc Ordinary Shares (NYSE:AGN) shares. They now have a $273 target price on the company. Deutsche Bank’s target means a potential upside of 10.39 % from the company’s stock close price.

Investors sentiment decreased to 0.5 in 2016 Q4. Its down 3.50, from 4 in 2016Q3. It turned negative, as 4 investors sold Allergan plc Ordinary Shares shares while 4 reduced holdings. 2 funds opened positions while 2 raised stakes. 69,049 shares or 57.17% less from 161,234 shares in 2016Q3 were reported.

Frontier Investment Mgmt invested 0.78% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Chartist Inc Ca reported 1,562 shares or 0% of all its holdings. Mitchell Mcleod Pugh Williams Inc reported 0.68% stake. Cubic Asset Mngmt Limited Liability Company holds 2,100 shares. Legacy Capital Prns Inc reported 1,940 shares. Connors Investor Service holds 1,000 shares. Gemmer Asset Limited Liability Company holds 0.01% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 120 shares. Eqis Cap Mgmt Inc owns 5,297 shares. Dowling & Yahnke Limited Company stated it has 1,530 shares. Amer Rech & Mngmt Company holds 33 shares. 463 were reported by Bartlett And Limited Liability Corporation. Grassi Investment reported 8,275 shares. Armstrong Henry H Assoc has 0.16% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 3,690 shares.

Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage

Among 22 analysts covering Allergan Inc. (NYSE:AGN), 16 have Buy rating, 0 Sell and 6 Hold. Therefore 73% are positive. Allergan Inc. has $400 highest and $23100 lowest target. $295.55’s average target is 19.51% above currents $247.31 stock price. Allergan Inc. had 60 analyst reports since July 29, 2015 according to SRatingsIntel. On Wednesday, May 10 the stock rating was maintained by RBC Capital Markets with “Outperform”. As per Thursday, June 29, the company rating was maintained by Cowen & Co. The rating was initiated by Nomura on Tuesday, September 29 with “Buy”. The stock has “Buy” rating by Mizuho on Friday, November 13. The company was downgraded on Thursday, April 7 by Susquehanna. The firm has “Neutral” rating given on Monday, April 18 by Guggenheim. The rating was maintained by Leerink Swann on Monday, September 21 with “Buy”. On Wednesday, May 10 the stock rating was downgraded by Goldman Sachs to “Neutral”. Mizuho maintained it with “Buy” rating and $293.0 target in Tuesday, November 1 report. The firm earned “Neutral” rating on Friday, May 13 by Mizuho.

About 1.02M shares traded. Allergan plc Ordinary Shares (NYSE:AGN) has declined 3.42% since July 17, 2016 and is downtrending. It has underperformed by 20.12% the S&P500.

More notable recent Allergan plc Ordinary Shares (NYSE:AGN) news were published by: Investorplace.com which released: “Is Allergan plc Ordinary Shares (AGN) Snapping Out of It?” on December 29, 2016, also Investorplace.com with their article: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” published on September 20, 2016, Schaeffersresearch.com published: “Biotech Buyout Fuels Unusual Options Activity on Allergan plc Ordinary Shares …” on September 20, 2016. More interesting news about Allergan plc Ordinary Shares (NYSE:AGN) were released by: Bloomberg.com and their article: “Allergan is Not Going to Buy Gilead” published on September 22, 2016 as well as Investorplace.com‘s news article titled: “Zeltiq Aesthetics Inc (ZLTQ) Stock Soars on$2.5B Allergan (AGN) Deal” with publication date: February 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.